Vorinostat
- Generic Name
- Vorinostat
- Brand Names
- Zolinza
- Drug Type
- Small Molecule
- Chemical Formula
- C14H20N2O3
- CAS Number
- 149647-78-9
- Unique Ingredient Identifier
- 58IFB293JI
- Background
Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase...
- Indication
用于治疗加重、持续和复发或用两种全身性药物治疗后无效的T细胞淋巴瘤(CTCL, 一种非霍奇金淋巴瘤)。
- Associated Conditions
- Cutaneous T-Cell Lymphoma Recurrent, Persistent Cutaneous T-Cell Lymphoma, Progressive Cutaneous T-cell lymphoma
- Associated Therapies
- -
Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2008-08-07
- Last Posted Date
- 2020-05-18
- Target Recruit Count
- 19
- Registration Number
- NCT00729118
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma
- First Posted Date
- 2008-07-23
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT00720876
- Locations
- 🇺🇸
City of Hope Medical Group, Pasadena, California, United States
🇺🇸Tower Cancer Research Foundation, Beverly Hills, California, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer
- First Posted Date
- 2008-07-22
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Yale University
- Target Recruit Count
- 24
- Registration Number
- NCT00719875
- Locations
- 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2008-06-23
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 65
- Registration Number
- NCT00703664
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States
Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2008-06-05
- Last Posted Date
- 2020-11-20
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 40
- Registration Number
- NCT00691210
- Locations
- 🇺🇸
Center for Lymphoid Malignancies at CUMC, New York, New York, United States
Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Myelomonocytic Leukemia (M4)Untreated Adult Acute Myeloid LeukemiaAdult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Erythroleukemia (M6a)Adult Pure Erythroid Leukemia (M6b)Adult Acute Myeloblastic Leukemia With Maturation (M2)
- Interventions
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2017-06-01
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 31
- Registration Number
- NCT00673153
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III Non-Small Lung Cancer That Cannot Be Removed By Surgery
- Conditions
- Interventions
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 5
- Registration Number
- NCT00662311
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2008-04-11
- Last Posted Date
- 2015-03-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 106
- Registration Number
- NCT00656617
- Locations
- 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)
- Conditions
- Interventions
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2020-11-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 31
- Registration Number
- NCT00642954
Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme
- First Posted Date
- 2008-03-24
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 44
- Registration Number
- NCT00641706
- Locations
- 🇺🇸
Rush - Copley Medical Center, Aurora, Illinois, United States
🇺🇸Galesburg Cottage Hospital, Galesburg, Illinois, United States
🇺🇸Illinois CancerCare Galesburg, Galesburg, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.